1）Brown JM, Wilson WR. Exploiting tumour hypoxia in 2）Kaneko K, Yamaguchi H, Saito T, Yano T, Oono Y, Ikematsu H, et al. Hypoxia imaging endoscopy equipped with laser light source from preclinical live animal study to first-in-human subject research. PLoS One 2014; 9(6): e99055.3）Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 2007; 98(6): 779-89.5）Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19(11): 1437-48.cancer treatment. Nat Rev Cancer 2004; 4(6): 437-47.4）Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372(20): 1909-19.6）Matsuoka K, Nakagawa F, Kobunai T, Takechi T. Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression. Oncotarget 2018; 9(17): 13438-50.7）Harada H, Kizaka-Kondoh S, Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 2005; 4(3): 182-93.8）Zhang G, Palmer GM, Dewhirst MW, Fraser CL. A dual-emissive-materials design concept enables tumour hypoxia imaging. Nat Mater 2009; 8(9): 747-51.9）Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep 2015; 33(5): 2135-42.10）Suzuki N, Nakagawa F, Matsuoka K, Takechi T. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts. Oncol Rep 2016; 36(6): 3123-30.151文 献
元のページ ../index.html#167